Cecilia Brown

DocwireNews

Osimertinib (Tagrisso) plus pemetrexed and platinum-based chemotherapy has been approved in China as a first-line treatment for adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) who have exon 19 deletions or exon 21 (L858R) mutations, according to an announcement from AstraZeneca.The approval by China&rsquo;s National Medical Products Administration was based on results from the phase 3 FLAURA2 trial that were published in the New England Journal of Medicine, as well as results from a prespecified exploratory subgroup analysis of efficacy and safety in Chinese patients that were presented at the European Society for Medical Oncology Asia Congress 2023, according to the announcement.&ldquo;The approval of osimertinib with the addition of chemotherapy in China is critical for the treatment of the largest population of patients with EGFR-mutated lung cancer worldwide,&rdquo; Ying Cheng, MD, director of the Jilin Lung Cancer Diagnosis and Treatment Centre and principal investigator in China, said in a statement. &ldquo;These patients will now have a choice of two highly effective osimertinib-based options for first-line treatment, allowing physicians to tailor their approach to their patients. This is especially important for those with a poorer prognosis, such as cancer that has spread to the brain or those who have L858R mutations.&rdquo;AstraZeneca officials said that in the overall FLAURA2 trial population, osimertinib plus chemotherapy reduced the risk of disease progression or death by 38%, compared with osimertinib monotherapy, which is &ldquo;the first-line global standard of care&rdquo; (hazard ratio [HR], 0.62; 95% CI, 0.49-0.79; P&lt;.0001). The median progression-free survival (PFS) was 25.5 months for patients receiving osimertinib plus chemotherapy, 8.8 months longer than the median PFS of 16.7 months seen in patients receiving osimertinib monotherapy.Efficacy results from the China cohort of FLAURA2 were &ldquo;broadly consistent with the overall trial,&rdquo; according to the announcement, which stated that osimertinib plus chemotherapy reduced the risk of disease progression or death by 44% compared with osimertinib monotherapy (HR, 0.56; 95% CI, 0.34-0.92). The median PFS was 27.4 months for patients receiving osimertinib plus chemotherapy, 5.1 months longer than the median PFS of 22.3 months in those receiving monotherapy.&ldquo;Tagrisso with the addition of chemotherapy in FLAURA2 has not only shown unprecedented [PFS] in the overall trial population, but also among Chinese patients, reducing the risk of disease progression by nearly half,&rdquo; Dave Fredrickson, executive vice president, Oncology Business Unit, AstraZeneca, said in a statement. &ldquo;This approval reinforces Tagrisso as a backbone therapy in EGFR-mutated lung cancer and acknowledges its important role, as monotherapy or with chemotherapy, in addressing the high prevalence of this disease in Asian countries and China, specifically.&rdquo;Osimertinib is approved as monotherapy in more than 100 countries, including the United States, the European Union, China, and Japan. The approved indications include as a first-line treatment for patients with locally advanced or metastatic EGFR-mutated NSCLC, locally advanced or metastatic EGFR T790M mutation-positive NSCLC, and adjuvant treatment of early-stage EGFR-mutated NSCLC. In addition to the new approval in China, osimertinib plus chemotherapy is also approved in the United States and several other countries as a first-line treatment of patients with locally advanced or metastatic EGFR-mutated NSCLC.Source: <a href="https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-with-the-addition-of-chemotherapy-approved-in-china-as-1st-line-treatment-for-patients-with-egfr-mutated-advanced-lung-cancer.html">AstraZeneca</a>

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Osimertinib Plus Chemotherapy Approved in China as First-Line Treatment for EGFR-Mutated Advanced NSCLC

Non-Small Cell Lung Cancer

Osimertinib (Tagrisso) plus pemetrexed and platinum-based chemotherapy has been approved in China as a first-line treatment for adults with certain forms of NSCLC.

Osimertinib Plus Chemotherapy Approved in China as First-Line Treatment for EGFR-Mutated NSCLC

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe